This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation
substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with
carboplatin or paclitaxel, to determine the safety and tolerability of increasing doses of
BAL0891 in patients with advanced solid tumors.